21 completed, 4 active not recruiting, 3 unknown, 2 not yet recruiting. 34 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 21, Active not recruiting 4, Unknown 3, Not yet recruiting 2, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
| Phase 3 | 2 | Unknown 2 |
Follow Chickenpox: new trials by email Literature Review of Chickenpox trials Research Report on Chickenpox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants HZ Vaccine (IN001), Shingrix - Herpes Zoster | Phase 2 | Not yet recruiting | Shenzhen Shenxin Biotechnology Co., Ltd | 480 | 2026-05-01 | 2025-10-07 |
| Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above Shingrix, CVI-VZV-001 - Herpes Zoster | Phase 2 | Active not recruiting | Aribio Lab Co., Ltd. | 135 | 2026-04-17 | 2026-10-28 |
| Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation Booster dose of the recombinant zoster vaccine (RZV, Shingrix®) - Zoster; Herpes | Phase 2 | Not yet recruiting | Oriol Manuel | 75 | 2026-04-01 | 2026-03-02 |
| Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above ABO1108, Placebo - Varicella-zoster Virus | Phase 2 | Active not recruiting | Suzhou Abogen Biosciences Co., Ltd. | 300 | 2025-11-15 | 2026-05-11 |
| A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ), Shingles | Phase 2 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 840 | 2025-10-23 | 2025-12-30 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine - Measles; Mumps; Rubella; Chickenpox, Measles | Phase 2 | Completed | GlaxoSmithKline | 801 | 2022-12-14 | 2025-06-22 |
| Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination MG1111 (BARICELA), VARIVAX, Suduvax - Varicella | Phase 2 | Recruiting | Green Cross Corporation | 230 | 2022-07-05 | 2024-01-24 |
| A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency - Chickenpox | Phase 2 | Completed | GlaxoSmithKline | 800 | 2022-02-03 | 2025-02-28 |
| Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix - Herpes Zoster, Shingles | Phase 2 | Active not recruiting | Curevo Inc | 1516 | 2022-02-02 | 2025-09-30 |
| Systems Biology of Zoster Vaccine Shingrix® - Zoster, Zoster Varicella | Phase 2 | Completed | Emory University | 38 | 2019-11-14 | 2024-07-30 |
| The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age NBP608, Varivax - Varicella | Phase 2 | Completed | SK Chemicals Co., Ltd. | 152 | 2016-05-01 | 2017-04-14 |
| Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study Zostavax - Herpes Zoster | Phase 1 / Phase 2 | Withdrawn | University of Zurich | 2010-12-01 | 2013-03-01 | |
| Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation - Measles, Varicella | Phase 2 | Completed | GlaxoSmithKline | 501 | 2009-06-03 | 2019-11-15 |
| Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery Varicella Vaccine, Hepatitis A Vaccine - Varicella, Hepatitis A | Phase 2 / Phase 3 | Unknown | University of Sao Paulo General Hospital | 600 | 2009-06-01 | 2009-06-23 |
| Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy ZOSTAVAX, Placebo - Herpes Zoster, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 395 | 2009-04-29 | 2021-11-04 |
| Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years Herpes zoster vaccine GSK1437173A, Placebo - Herpes Zoster | Phase 2 | Completed | GlaxoSmithKline | 410 | 2009-01-12 | 2019-06-26 |
| Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles) ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir - Herpes Zoster, Postherpetic Neuralgia | Phase 2 | Unknown | aRigen Pharmaceuticals, Inc. | 300 | 2008-03-01 | 2008-10-07 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix® - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 1851 | 2007-11-20 | 2018-10-09 |
| Study of Two Formulations of GSK Biologicals' Varicella Vaccine Varilrix (inactivated varicella vaccine) - Varicella | Phase 2 | Completed | GlaxoSmithKline | 244 | 2007-11-01 | 2018-06-08 |
Showing 20 of 34. Sign in to see all of them.
Herpes Zoster (16) · Measles (8) · Mumps (8) · Rubella (8) · Neuralgia, Postherpetic (3) · HIV Infections (2) · Neuralgia (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Blister (1) · DNA Virus Infections (1) · Depression (1) · Exanthema (1) · Hepatitis A (1)
DNA Virus Infections (33) · Herpesviridae Infections (33) · Infections (33) · Varicella Zoster Virus Infection (33) · Virus Diseases (33) · RNA Virus Infections (11) · Mononegavirales Infections (8) · Morbillivirus Infections (8) · Mouth Diseases (8) · Paramyxoviridae Infections (8) · Parotid Diseases (8) · Parotitis (8) · Rubivirus Infections (8) · Rubulavirus Infections (8) · Salivary Gland Diseases (8)
Chickenpox Vaccine (4) · Hepatitis A Vaccines (3) · measles, mumps, rubella, varicella vaccine (3) · Herpes Zoster Vaccine (2) · Measles-Mumps-Rubella Vaccine (2) · sorivudine (2) · Acyclovir (1) · Antigens (1) · Blood Specimen Collection (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Injections (1) · Rubella Vaccine (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1) · Sodium Chloride (1) · Suspensions (1)
GlaxoSmithKline (11) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Merck Sharp & Dohme LLC (2) · Aribio Lab Co., Ltd. (1) · Curevo Inc (1) · Emory University (1) · Green Cross Corporation (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · National Institute on Aging (NIA) (1) · NeurogesX (1) · Oriol Manuel (1) · Pfizer (1) · SK Chemicals Co., Ltd. (1) · SK Life Science, Inc. (1)
United States (14) · Czechia (3) · Taiwan (3) · China (2) · Germany (2) · Italy (2) · Puerto Rico (2) · South Korea (2) · Switzerland (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Estonia (1)
Barbara Hasse, MD (1) · Constance A. Benson, MD (1) · Crumpacker C (1) · Glacus S Brito, MD (1) · Guy De La Rosa, MD (1) · Jeffrey L. Lennox, MD (1) · John A Jermano (1) · Klara M Posfay-Barbe, MD, MS (1) · Lisa Shelton, ARNP (1) · Michael R. Irwin, MD (1) · Nadine Rouphael, MD (1)
PMID 16094218, PMID 18652095, PMID 19469706, PMID 21934474, PMID 22872734, PMID 25272081, PMID 26762528, PMID 29461919, PMID 29590326, PMID 30975567, PMID 41825190
2008 (1), R01AG018367 (1), U19AI090023 (1)